市場調查報告書
商品編碼
1463588
亞太地區牛隻診斷市場預測至 2030 年 - 區域分析 - 按產品、疾病類型和最終用戶(獸醫醫院、獸醫診所和其他最終用戶)Asia Pacific Bovine Diagnostics Market Forecast to 2030 - Regional Analysis - by Product, Disease Type, and End User (Veterinary Hospitals, Veterinary Clinics, and Other End-Users) |
亞太地區牛CAGR診斷市場預計將從2022年的2.5042億美元成長到2030年的4.8294億美元。
牛結核病的高盛行率推動了亞太牛診斷市場
牛結核病(bTB)是一種慢性傳染病,主要影響牛,隨後傳播給其他動物和人類。世界動物衛生組織(WOAH)已將bTB列為必須儘早發現和報告的疾病之一。根據賽默飛世爾科技 2023 年 5 月分享的資料,bTB 影響全球超過 5,000 萬頭牛,每年造成約 30 億美元的經濟損失。
不同地理區域的 bTB 盛行率有所不同。然而,在亞洲某些地區,bTB 的盛行率超過 50%。儘管技術和基礎設施不斷發展,但由於疾病的複雜性和缺乏通用的診斷策略,許多國家未能有效診斷 bTB。這種情況為牛隻診斷市場參與者提供了提高亞洲意識並推出適合這些國家社會經濟條件的新產品的機會。
亞太地區牛隻診斷市場概況
亞太地區的牛隻診斷市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。根據 2023 年 BMC 期刊發表的一篇文章,bTB 是中國的一種主要流行病,導致乳牛生產遭受重大損失。農業農村部在《國家中長期動物疫病防治規劃(2012-2020年)》中,將乳牛結核病列為重點防治的16種傳染病之一。人類福祉。對牛布魯氏菌病、牛支原體病、副結核病和牛白血病等疾病進行基於牛奶的檢測。牛奶樣本的採集和檢測對乳牛沒有太大影響,這也導致乳牛工人更加配合。中國的國家乳牛群改良(DHI)計畫也強調每月從泌乳牛身上採集牛奶樣本,然後進行檢測,以評估繁殖適宜性和牛奶品質。它還建議使用 CombiFoss FT + 牛奶成分和體細胞分析儀評估牛奶樣本,以在早期階段檢測乳腺炎。中國透過檢測和屠宰政策來實施目前的牛結核病控制策略,該政策以國家和地方各級以及農場的監測計畫為基礎。牛分枝桿菌培養是診斷 bTB 的「黃金標準」。然而,透過培養鑑定牛支原體不靈敏、繁瑣、耗時,並且由於該病原體具有持續感染、生長緩慢和潛在危險的特性,需要高水準的生物安全實驗室設施。目前,結核菌素皮膚試驗是中國農場動物檢測bTB的建議和常規測試,而血液γ干擾素體外釋放試驗是另一種實驗室診斷測試。因此,bTB疾病的增加和政府對診斷的支持促進了中國牛隻診斷市場的成長。
亞太地區牛隻診斷市場收入及 2030 年預測(百萬美元)
亞太地區牛診斷市場細分
亞太地區牛隻診斷市場按產品、疾病類型、最終用戶和國家細分。
根據產品,亞太牛診斷市場分為免疫檢測試劑盒、PCR 試劑和試劑盒、血凝抑制 (HI) 檢測和其他產品。 2022 年,免疫分析試劑盒領域在亞太牛診斷市場中佔最大佔有率。
根據疾病類型,亞太牛診斷市場分為牛病毒性腹瀉(BVD)、牛結核病(TB)、牛乳房炎、口蹄疫(FMD)和其他疾病類型。 2022 年,牛乳房炎細分市場在亞太牛診斷市場中佔據最大佔有率。
根據最終用戶,亞太牛診斷市場分為獸醫醫院、獸醫診所和其他最終用戶。 2022年,獸醫院細分市場在亞太地區牛隻診斷市場中佔據最大佔有率。
根據國家/地區,亞太地區牛隻診斷市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2022年,中國將主導亞太牛診斷市場。
BioMerieux SA、Bionote Inc、Idex Laboratories Inc、Innovative Diagnostics SAS、Neogen Corp、Ring Biotechnology Co Ltd、深圳市易易生物科技有限公司和 Thermo Fisher Scientific Inc 是亞太牛診斷市場上的一些領先公司。
The Asia Pacific bovine diagnostics market is expected to grow from US$ 250.42 million in 2022 to US$ 482.94 million by 2030. It is estimated to grow at a CAGR of 8.6% from 2022 to 2030.
High Prevalence of Bovine Tuberculosis Fuels Asia Pacific Bovine Diagnostics Market
Bovine tuberculosis (bTB) is a chronic infectious disease that primarily affects cattle and is later transmitted to other animals and humans. The World Organization for Animal Health (WOAH) has listed bTB as one of the diseases that must be detected and reported as earliest as possible. As per the data shared by Thermo Fisher Scientific in May 2023, bTB affects more than 50 million cattle worldwide, incurring annual economic losses of ~US$ 3 billion.
The prevalence of bTB differs in different geographic areas. However, its prevalence reaches beyond bTB 50% in some parts of Asia. Despite the ongoing technological and infrastructural developments, many countries fail to effectively diagnose bTB due to the complexity of the disease and the lack of universal strategies for its diagnosis. This scenario provides opportunities for bovine diagnostics market players to enhance awareness in Asia and launch new products that suit the socioeconomic conditions in these countries.
Asia Pacific Bovine Diagnostics Market Overview
The Asia Pacific bovine diagnostics market in Asia Pacific is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to an article published in BMC Journals in 2023, bTB is a major endemic in China that results in major losses in dairy cattle production. In its Medium and Long-Term National Plan for Prevention and Control of Animal Diseases (2012-2020), the Ministry of Agriculture and Rural Affairs in China has classified the bTB of dairy cattle as one of the 16 infectious diseases that should be controlled and eliminated, as the disease also affects human welfare in addition to the livestock industry. A milk-based test is performed for diseases such as bovine brucellosis, Mycoplasma bovis (M. bovis) disease, paratuberculosis, and bovine leukosis. The collection and testing of milk samples do not have much impact on dairy cows, which also results in greater cooperation from dairy workers. The National Dairy Herd Improvement (DHI) Program of China also emphasizes on the collection of milk samples from lactating cows monthly, followed by testing them to assess breeding suitability and milk quality. It also recommends evaluating the milk samples to detect mastitis in the early stages using a CombiFoss FT + milk composition and a somatic cell analyzer. China implements its current bTB control strategy through test-and-slaughter policies, which are based on surveillance programs at the national and local levels, as well as on farms. Mycobacterium bovis culture is the "gold standard" for diagnosing bTB. However, the identification of M. bovis by culturing it is insensitive, cumbersome, and time-consuming, and it requires high-level biosafety laboratory facilities because of the persistent infection, slow growth, and potentially dangerous characteristics of the pathogen. Currently, the tuberculin skin test is the recommended and conventional test performed on animals at farms in China for detecting bTB, while the blood interferon-gamma in vitro release test is an alternative laboratory diagnostic test available. Thus, increasing bTB disease and support by government for diagnosis boosts the growth of bovine diagnostics market growth in China.
Asia Pacific Bovine Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Bovine Diagnostics Market Segmentation
The Asia Pacific bovine diagnostics market is segmented into product, disease type, end user, and country.
Based on product, the Asia Pacific bovine diagnostics market is segmented into immunoassay kits, PCR reagents & kits, hemagglutination inhibition (HI) assay, and other products. The immunoassay kits segment held the largest share of the Asia Pacific bovine diagnostics market in 2022.
Based on disease type, the Asia Pacific bovine diagnostics market is segmented into bovine viral diarrhea (BVD), bovine tuberculosis (TB), bovine mastitis, foot and mouth disease (FMD), and other disease types. The bovine mastitis segment held the largest share of the Asia Pacific bovine diagnostics market in 2022.
Based on end user, the Asia Pacific bovine diagnostics market is segmented into veterinary hospitals, veterinary clinics, and other end-users. The veterinary hospitals segment held the largest share of the Asia Pacific bovine diagnostics market in 2022.
Based on country, the Asia Pacific bovine diagnostics market is segmented int o China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific bovine diagnostics market in 2022.
bioMerieux SA, Bionote Inc, Idexx Laboratories Inc, Innovative Diagnostics SAS, Neogen Corp, Ring Biotechnology Co Ltd, Shenzhen Bioeasy Biotechnology Co Ltd, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific bovine diagnostics market.